OHSU in the news

After long wait, Editas reveals first data for CRISPR gene editing treatment

BioPharma Dive September 29, 2021
A clinical trial evaluating a CRISPR-based gene editing technology to remove gene mutations that cause a form of blindness sees success. OHSU's Mark Pennesi, M.D., Ph.D., describes how two trial participants have experienced improved eyesight, including OHSU participant Carlene Knight who says she can now see more clearly.

Editas early data for CRISPR therapy EDIT-101 shows efficacy “signals” in two patients

Generic Engineering & Biotechnology News September 29, 2021
“I am encouraged by these initial results, which indicate this investigational gene editing treatment has been well-tolerated in this trial’s participants thus far and may also help improve sight for people with mutations in the CEP290 gene,” stated Mark Pennesi, MD, PhD, of Oregon Health & Science University, where he is a Professor of Molecular and Medical Genetics, Kenneth C. Swan Endowed Professor of Ophthalmology, and Paul H. Casey Ophthalmic Genetics Division Chief for OHSU’s Casey Eye Institute.

A gene-editing experiment let these patients with vision loss see color again

NPR's Science Friday September 29, 2021
In coverage of initial results for a clinical trial evaluating a CRISPR-based gene editing technology to remove gene mutations that cause a form of blindness, OHSU's Mark Pennesi, M.D., Ph.D., describes how two trial participants have experienced improved eyesight, including OHSU participant Carlene Knight who says she can now see more clearly.

Thousands of Oregon healthcare workers remain unvaccinated as deadlines loom

The Oregonian September 29, 2021
To help ensure its hospitals and clinics remain as safe as possible for the long term, OHSU requires all members -- employees, learners and volunteers institution-wide -- be fully vaccinated against COVID-19 or receive an approved medical or religious exception by Oct. 18.

Low-dose aspirin guards against preeclampsia task force

HealthDay September 28, 2021
The U.S. Preventive Services Task Force recommends low-dose aspirin during the first trimester of pregnancy to limit risks of preeclampsia; OHSU's Aaron Caughey, M.D., Ph.D., says: “We know that aspirin interacts with some molecules in the bloodstream that are related to inflammation, and we think it impacts the way the placenta implants in the uterus.”
See more stories